Barclays
http://www.barclays.com/Barclays plc is a global financial services provider engaged in retail and commercial banking, credit cards, investment banking, wealth management and investment management services. It has an extensive international presence in Europe, the United States, Africa and Asia. In addition, the bank is one of the ten largest banks in the world measured by market capitalization. Barclays is headquartered in London, England.
View Older Stories View More Recent Stories
-
Morgan Stanley (MS) Could Run if French Exposure Bests Expectations - Barron's
-
Barclays U.S. Portfolio Strategy Weekly: Over Promise and Under Deliver
-
Barclays Downgrades Dollar Tree (DLTR) to Equalweight
-
Barclays Upgrades Family Dollar Stores Inc. (FDO) to Overweight
-
Barclays on Power & Utilities: Weekly Preview
-
Barclays on U.S. Retail Softlines: Pak's Short Interest Monitor
-
Barclays Maintains an 'Overweight' on Microchip Technology (MCHP); Chirps Again, More Semis to Follow
-
Barclays Maintains an 'Equalweight' on Yum! Brands (YUM); Management Meetings; Top 10 Takeaways
-
Barclays Maintains an 'Overweight' on Wal-Mart (WMT); Further Review of Analyst Day
-
Barclays maintains an 'Equalweight' onSAFEWAY (SWY); Still Running Uphill
-
Barclays maintains an 'Equalweight' on PetSmart (PETM); Raising Estimates
-
Barclays Maintains an 'Equalweight' on Liz Claiborne (LIZ); Transforming the Business
-
Barclays Maintains an 'Equalweight' on Gap, Inc. (GPS); Highlights from GPS Investor Day
-
Barclays Maintains an 'Equalweight' on National CineMedia (NCMI); 3Q Reiterated, But 4Q Guidance Lowered
-
Barclays Maintains an 'Overweight' on Google (GOOG); Paid Click Growth Drives Topline Upside - Remains Top Pick
-
Barclays Reiterates an 'Overweight' on Johnson Controls (JCI); Confidence in Margin Expansion Grows
-
Barclays on Medical Supplies & Devices: Adjusting Estimates for Approval Timing
-
Barclays on U.S. Large-Cap & Mid-Cap Banks: Top 5 Laterals from JPM's EPS 3Q Release
-
Barclays Maintains an 'Overweight' on FXCM Inc (FXCM); Historically Strong, but Below Expectation Volumes - Lowering 3Q11E EPS
-
Barclays maintains an 'Equalweight' on Eaton Vance (EV): September AUM Reflects QTD Outflows
-
Barclays Maintains an 'Equalweight' on Montpelier Re Holdings (MRH); Reducing 3Q11 EPS
-
Barclays Maintains an 'Overweight' on JPMorgan (JPM); 3Q11 EPS Review: 'Capital Confusion' & Tempered Investment Bank Expectations
-
Barclays on U.S. Multi-Industry: Initiating Coverage: Cash Will Drive Outperformance - Scale in to Year-End
-
Barclays Starts Roper Industries (ROP) at Overweight, $96 Price Target
-
Barclays Starts Sensata Technologies (ST) at Overweight, $39 Price Target
-
Barclays Starts SPX Corp. (SPW) at Overweight, $70 Price Target
-
Barclays Starts Thomas & Betts (TNB) at Overweight, $53 Price Target
-
Barclays Starts Tyco International (TYC) at Equalweight, $48 Price Target
-
Barclays Starts Watsco (WSO) at Underweight, $59 Price Target
-
Barclays Starts WESCO International (WCC) at Overweight, $55 Price Target
-
Barclays Starts WW Grainger (GWW) at Overweight, $183 Price Target
-
Barclays Starts MSC Industrial (MSM) at Overweight, $76 Price Target
-
Barclays Starts Rockwell Automation (ROK) at Overweight, $88 Price Target
-
Barclays Starts Lennox International (LII) at Underweight, $29 Price Target
-
Barclays Starts 3M (MMM) at Equalweight, $94 Price Target
-
Barclays Starts Honeywell International (HON) at Overweight, $69 Price Target
-
Barclays Starts Cooper Industries (CBE) at Overweight, $62 Price Target
-
Barclays Starts Hubbell (HUBB) at Overweight, $64 Price Target
-
Barclays Starts Ingersoll-Rand (IR) at Equalweight, $36 Price Target
-
Barclays Starts ITT Corp. (ITT) at Equalweight, $46 Price Target
-
Barclays Starts Danaher (DHR) at Overweight, $53 Price Target
-
Barclays Starts Dover Corp. (DOV) at Equalweight, $67 Price Target
-
Barclays Starts Emerson (EMR) at Equalweight, $55 Price Target
-
Barclays Starts Fastenal (FAST) at Underweight, $33 Price Target
-
Barclays Starts General Electric (GE) at Overweight, $20 Price Target
-
Barclays Starts Colfax Corporation (CFX) at Equalweight, $29 Price Target
-
Barclays Downgrades GlaxoSmithKline (GSK) to Equalweight
-
Barclays Reiterates an 'Overweight' on Intel (INTC); Still A Defensive Play in the Current Uncertain Demand Environment
-
Barclays Maintains an 'Overweight' on ADTRAN (ADTN); Estimates Lower Given Weak Guidance
-
Barclays Maintains an 'Overweight' on Wal-Mart (WMT); Don't Pull the Plug
